Voyager Therapeutics Inc to Post Q2 2020 Earnings of ($0.80) Per Share, Wedbush Forecasts (NASDAQ:VYGR)
Voyager Therapeutics Inc (NASDAQ:VYGR) – Research analysts at Wedbush issued their Q2 2020 EPS estimates for shares of Voyager Therapeutics in a research note issued to investors on Monday, August 12th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.80) per share for the quarter. Wedbush has a “Outperform” rating and a $36.00 price objective on the stock. Wedbush also issued estimates for Voyager Therapeutics’ Q3 2020 earnings at ($0.84) EPS and Q4 2020 earnings at ($0.87) EPS.
Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Friday, August 9th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $1.17. Voyager Therapeutics had a negative net margin of 106.23% and a negative return on equity of 82.98%. The firm had revenue of $46.09 million for the quarter, compared to analyst estimates of $5.25 million.
Voyager Therapeutics stock opened at $20.62 on Wednesday. Voyager Therapeutics has a 1-year low of $7.76 and a 1-year high of $28.79. The firm has a market capitalization of $791.41 million, a price-to-earnings ratio of -7.50 and a beta of 2.55. The firm’s fifty day moving average price is $24.00 and its two-hundred day moving average price is $20.68.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC increased its holdings in Voyager Therapeutics by 1.0% during the first quarter. Acadian Asset Management LLC now owns 46,500 shares of the company’s stock worth $890,000 after buying an additional 469 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in Voyager Therapeutics during the second quarter worth about $27,000. NumerixS Investment Technologies Inc purchased a new stake in Voyager Therapeutics during the second quarter worth about $30,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Voyager Therapeutics by 371.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,126 shares of the company’s stock worth $58,000 after buying an additional 1,675 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in Voyager Therapeutics by 15.8% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,174 shares of the company’s stock worth $252,000 after buying an additional 1,794 shares during the last quarter. 73.92% of the stock is currently owned by institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Read More: Asset Allocation
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.